These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 26501458)

  • 1. Chewing-gum stimulation did not reduce the absorbed dose to salivary glands during radioiodine treatment of thyroid cancer as inferred from pre-therapy (124)I PET/CT imaging.
    Jentzen W; Richter M; Nagarajah J; Poeppel TD; Brandau W; Dawes C; Bockisch A; Binse I
    EJNMMI Phys; 2014 Dec; 1(1):100. PubMed ID: 26501458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging.
    Jentzen W; Balschuweit D; Schmitz J; Freudenberg L; Eising E; Hilbel T; Bockisch A; Stahl A
    Eur J Nucl Med Mol Imaging; 2010 Dec; 37(12):2298-306. PubMed ID: 20625723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrepant salivary gland response after radioiodine and MIBG therapies.
    Jentzen W; Richter M; Poeppel TD; Schmitz J; Brandau W; Bockisch A; Binse I
    Q J Nucl Med Mol Imaging; 2017 Sep; 61(3):331-339. PubMed ID: 25566809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-therapeutic (124)I PET(/CT) dosimetry confirms low average absorbed doses per administered (131)I activity to the salivary glands in radioiodine therapy of differentiated thyroid cancer.
    Jentzen W; Hobbs RF; Stahl A; Knust J; Sgouros G; Bockisch A
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):884-95. PubMed ID: 20069293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between cumulative radiation dose and salivary gland uptake associated with radioiodine therapy of thyroid cancer.
    Jentzen W; Schneider E; Freudenberg L; Eising EG; Görges R; Müller SP; Brandau W; Bockisch A
    Nucl Med Commun; 2006 Aug; 27(8):669-76. PubMed ID: 16829767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPECT/CT-based dosimetry of salivary glands and iodine-avid lesions following
    Abuqbeitah M; Demir M; Sağer S; Asa S; Işıkcı NI; Sönmezoğlu K
    Health Technol (Berl); 2023; 13(1):101-110. PubMed ID: 36628262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iodine kinetics and dosimetry in the salivary glands during repeated courses of radioiodine therapy for thyroid cancer.
    Liu B; Huang R; Kuang A; Zhao Z; Zeng Y; Wang J; Tian R
    Med Phys; 2011 Oct; 38(10):5412-9. PubMed ID: 21992360
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer?
    Nakada K; Ishibashi T; Takei T; Hirata K; Shinohara K; Katoh S; Zhao S; Tamaki N; Noguchi Y; Noguchi S
    J Nucl Med; 2005 Feb; 46(2):261-6. PubMed ID: 15695785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salivary gland protection with sialagogues: a case study.
    Van Nostrand D; Atkins F; Bandaru VV; Chennupati SP; Moreau S; Burman K; Wartofsky L
    Thyroid; 2009 Sep; 19(9):1005-8. PubMed ID: 19500022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of chewing-gum on dose rate of salivary gland in differentiated thyroid carcinoma patients treated with radioiodine.
    Haghighatafshar M; Nowshad R; Etemadi Z; Ghaedian T
    Q J Nucl Med Mol Imaging; 2020 Sep; 64(3):321-325. PubMed ID: 29696945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation Dosimetry for
    Okamoto S; Thieme A; Allmann J; D'Alessandria C; Maurer T; Retz M; Tauber R; Heck MM; Wester HJ; Tamaki N; Fendler WP; Herrmann K; Pfob CH; Scheidhauer K; Schwaiger M; Ziegler S; Eiber M
    J Nucl Med; 2017 Mar; 58(3):445-450. PubMed ID: 27660138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lowest effective 131I activity for thyroid remnant ablation of differentiated thyroid cancer patients. Dosimetry-based model for estimation.
    Jentzen W; Moldovan AS; Ruhlmann M; Görges R; Bockisch A; Rosenbaum-Krumme S
    Nuklearmedizin; 2015; 54(3):137-43. PubMed ID: 25987357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial.
    Liu B; Kuang A; Huang R; Zhao Z; Zeng Y; Wang J; Tian R
    J Nucl Med; 2010 Apr; 51(4):618-23. PubMed ID: 20237029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monte Carlo-based 3-dimensional dosimetry of salivary glands in radioiodine treatment of differentiated thyroid cancer estimated using 124I PET.
    Hobbs RF; Jentzen W; Bockisch A; Sgouros G
    Q J Nucl Med Mol Imaging; 2013 Mar; 57(1):79-91. PubMed ID: 23474639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.
    Song H; He B; Prideaux A; Du Y; Frey E; Kasecamp W; Ladenson PW; Wahl RL; Sgouros G
    J Nucl Med; 2006 Dec; 47(12):1985-94. PubMed ID: 17138741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-therapeutic blood dosimetry in patients with differentiated thyroid carcinoma using 124-iodine: predicted blood doses correlate with changes in blood cell counts after radioiodine therapy and depend on modes of TSH stimulation and number of preceding radioiodine therapies.
    Hartung-Knemeyer V; Nagarajah J; Jentzen W; Ruhlmann M; Freudenberg LS; Stahl AR; Bockisch A; Rosenbaum-Krumme SJ
    Ann Nucl Med; 2012 Nov; 26(9):723-9. PubMed ID: 22802008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Normal organ dosimetry for thyroid cancer patients treated with radioiodine as part of the multi-centre multi-national Horizon 2020 MEDIRAD project.
    Taprogge J; Vergara-Gil A; Leek F; Abreu C; Vávrová L; Carnegie-Peake L; Schumann S; Eberlein U; Lassmann M; Schurrat T; Luster M; Verburg FA; Vallot D; Vija L; Courbon F; Newbold K; Bardiès M; Flux G
    Eur J Nucl Med Mol Imaging; 2023 Sep; 50(11):3225-3234. PubMed ID: 37300572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
    Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of Follow-Up.
    Baudin C; Bressand A; Buffet C; Menegaux F; Soret M; Lê AT; Cardon T; Broggio D; Bassinet C; Huet C; Armengol G; Richardson DB; Leenhardt L; Bernier MO; Lussey-Lepoutre C
    Thyroid; 2023 Sep; 33(9):1100-1109. PubMed ID: 37300484
    [No Abstract]   [Full Text] [Related]  

  • 20. 124-iodine positron emission tomography/computed tomography dosimetry in pediatric patients with differentiated thyroid cancer.
    Freudenberg LS; Jentzen W; Marlowe RJ; Koska WW; Luster M; Bockisch A
    Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):690-3. PubMed ID: 18058605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.